Targeting Th17 cells in HIV-1 remission/cure interventions

Trends Immunol. 2022 Jul;43(7):580-594. doi: 10.1016/j.it.2022.04.013. Epub 2022 May 31.

Abstract

Since the discovery of HIV-1, progress has been made in deciphering the viral replication cycle and mechanisms of host-pathogen interactions that has facilitated the implementation of effective antiretroviral therapies (ARTs). Major barriers to HIV-1 remission/cure include the persistence of viral reservoirs (VRs) in long-lived CD4+ T cells, residual viral transcription, and lack of mucosal immunity restoration during ART, which together fuel systemic inflammation. Recently, T helper (Th)17-polarized cells were identified as major contributors to the pool of transcriptionally/translationally competent VRs. In this review, we discuss the functional features of Th17 cells that were elucidated by fundamental immunology studies in the context of autoimmunity. We also highlight recent discoveries supporting the possibility of extrapolating this knowledge toward the identification of new putative Th17-targeted HIV-1 remission/cure strategies.

Keywords: HIV-1 cure; Th17 cells; antiretroviral therapy; metabolic pathways; transcription factors; viral reservoirs.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4-Positive T-Lymphocytes
  • HIV Infections*
  • HIV-1*
  • Humans
  • Th17 Cells
  • Virus Latency